<DOC>
	<DOCNO>NCT01635816</DOCNO>
	<brief_summary>The propose Japanese Encephalitis ( JE ) Vaccine study four-arm double-blind randomize control single center trial evaluate , examine post-vaccination seroprotection titer , lot-to-lot consistency three lot JE live attenuate SA 14-14-2 vaccine manufacture new GMP facility , establish non-inferiority new vaccine comparison single lot vaccine manufacture exist facility . The study enroll total 1,000 Bangladeshi infant age 10 12 month . In addition provide immunogenicity data , JEV05 provide local safety data JE live attenuate SA 14-14-2 vaccine among Bangladeshi child . This first step secure licensure life-saving vaccine Bangladesh well provide data support WHO prequalification JE live attenuate SA 14-14-2 vaccine .</brief_summary>
	<brief_title>Immunogenicity SA 14-14-2 JE Vaccine</brief_title>
	<detailed_description>Vaccination effective intervention prevent JE associate morbidity mortality ( http : //www.who.int.nuvi/Je/en ) . JE live attenuate SA 14-14-2 vaccine use Asia two decade 400 million child . Chengdu Institute Biological Products ( CDIBP ) , Chinese manufacturer , produce JE live attenuate SA 14-14-2 vaccine since 1988 . It demonstrate safe immunogenic several observational case-control study provide protection least 5 year follow single dose . JE live attenuate SA 14-14-2 vaccine license use China , India , Nepal , South Korea , Sri Lanka , Thailand . Countries introduce JE vaccine national immunization program experience dramatic reduction JE incidence , lead WHO declare vaccination prefer JE control strategy.4 In order JE live attenuate SA 14-14-2 vaccine available purchase UNICEF GAVI broad international use , include Bangladesh , JE live attenuate SA 14-14-2 vaccine need undergo WHO prequalification . With technical support PATH , CDIBP establish new GMP facility , Building 208 JE production unit , maintain WHO standard . A GMP Certificate new facility issue 11/16/2011 . This certificate provide market authorization distribute new vaccine China . To achieve WHO prequalification , JE live attenuate SA 14-14-2 vaccine produce new GMP facility need show similarly safe immunogenic JE live attenuate SA 14-14-2 vaccine produce exist facility , JE viral vaccine production plant , need demonstrate lot-to-lot consistency . The propose JEV05 study four-arm double-blind randomize controlled single center trial test immunogenicity four lot JE live attenuate SA 14-14-2 vaccine - three lot manufacture new GMP facility one lot exist facility - total 1000 Bangladeshi infant age 10 12 month . The study conduct Matlab Health Demographic Surveillance System ( HDSS ) intervention area , rural site many vaccine trial conduct . A 5 ml blood sample collect child vaccination 28 day post-vaccination . The serum test use plaque reduction neutralization test ( PRNT ) JE neutralize antibody titer &gt; 1:10 consider seroprotective . The JEV05 trial provide immunogenicity data three vaccine lot produce new GMP facility compare vaccine lot produce prior exist plant . It also provide local immunogenicity safety data JE live attenuate SA 14-14-2 vaccine among Bangladeshi child . This first step secure licensure life-saving vaccine Bangladesh well provide data support WHO prequalification JE live attenuate SA 14-14-2 vaccine .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infant 's parent ( ) legal guardian ( ) willing provide sign informed consent . Healthy infant age 10 12 month enrollment reside Matlab HDSS intervention area complete dos EPI immunization ( BCG , DPT , HBV , Hib , OPV measles ) least 4 week prior enrollment . Acute medical illness without fever within last 72 hour axillary temperature ( ≥ 37.5°C ) time vaccination . Use antibiotic antipyretic within last 72 hour prior enrollment . Severely moderately malnourished infant ( &lt; 3 Z score ) . History prematurity ( &lt; 36 week pregnancy ) . Underlying medical condition failure thrive , inborn error metabolism , bronchopulmonary dysplasia , major congenital abnormality require surgery chronic treatment . History serious chronic disease ( e.g. , cardiac , renal , neurologic , metabolic , rheumatologic , hematologic , bleed disorder ) . Known suspected impairment immunologic function . History document suspected encephalitis meningitis . History seizure , include history febrile seizure , neurologic disorder . History JE infection . Prior receipt JE vaccine . Received measles vaccine within 4 week prior , schedule receive vaccination , conduct trial . Prior anticipate receipt immune globulin blood product , injected oral corticosteroid immune modulator therapy within 6 week administration study vaccine . Serious adverse reaction ( e.g . urticaria , angioedema , shock , breathlessness follow vaccination life threaten condition ) previous EPI vaccine . Unable attend schedule visit comply study procedure . Enrolled another clinical trial involve therapy . Any condition opinion investigator , would pose health risk child , interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>10 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>SA 14-14-2 JE vaccine</keyword>
	<keyword>Bangladesh</keyword>
</DOC>